NEOGENOMICS INC·4

Jun 17, 4:07 PM ET

TETRAULT LYNN A. 4

4 · NEOGENOMICS INC · Filed Jun 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Neogenomics (NEO) Director Lynn A. Tetrault Sells 5,307 Shares

What Happened Lynn A. Tetrault, a director of Neogenomics, reported the sale of 5,307 shares of Neogenomics common stock on June 15, 2026. The shares were sold in an open-market/private sale at $11.10 per share for a total sale value of $58,908. This was a sale (not a purchase) and is typically considered a routine insider disposition rather than an affirmative bullish purchase.

Key Details

  • Transaction date: June 15, 2026
  • Transaction type: Open market/private sale (Code S)
  • Price per share: $11.10; Shares sold: 5,307; Total proceeds: $58,908
  • Shares owned after transaction: Not specified in the provided filing details
  • Footnote: F1 — once vested, the shares of common stock are not subject to expiration
  • Filing: Form 4 filed June 17, 2026 (filed within the standard two-business-day reporting window)

Context Sales by directors can be for many personal or portfolio reasons and do not by themselves indicate a change in company prospects. The filing’s footnote notes these were vested shares that aren't subject to expiration; no indication was given of an option exercise, 10b5-1 plan, or gift in the provided details.

Insider Transaction Report

Form 4
Period: 2026-06-15
Transactions
  • Sale

    Common Stock

    2026-06-15$11.10/sh5,307$58,90886,115 total
Holdings
  • Common Stock

    (indirect: By IRA)
    7,000
  • Stock Option (Right to Buy)

    Exercise: $22.52From: 2020-06-06Exp: 2026-06-06Common Stock (2,136 underlying)
    2,136
  • Stock Option (Right to Buy)

    Exercise: $28.54From: 2021-05-28Exp: 2027-05-28Common Stock (3,448 underlying)
    3,448
  • Stock Option (Right to Buy)

    Exercise: $40.90From: 2022-06-02Exp: 2028-06-02Common Stock (3,714 underlying)
    3,714
  • Stock Option (Right to Buy)

    Exercise: $41.76From: 2022-10-11Exp: 2028-10-11Common Stock (972 underlying)
    972
  • Stock Option (Right to Buy)

    Exercise: $8.10From: 2023-06-10Exp: 2029-06-10Common Stock (13,882 underlying)
    13,882
  • Stock Option (Right to Buy)

    Exercise: $14.82From: 2024-08-10Exp: 2033-08-10Common Stock (8,353 underlying)
    8,353
  • Stock Option (Right to Buy)

    Exercise: $13.71From: 2025-06-01Exp: 2034-06-01Common Stock (8,672 underlying)
    8,672
  • Stock Option (Right to Buy)

    Exercise: $7.28From: 2026-06-01Exp: 2035-06-01Common Stock (16,107 underlying)
    16,107
  • Stock Option (Right to Buy)

    Exercise: $10.52From: 2027-06-01Exp: 2036-06-01Common Stock (11,069 underlying)
    11,069
  • Restricted Stock Unit

    [F1]
    Exercise: $0.00From: 2027-06-01Common Stock (15,970 underlying)
    15,970
Footnotes (1)
  • [F1]Once vested, the shares of common stock are not subject to expiration.
Signature
/s/ Ali Olivo, Attorney-in-Fact|2026-06-17

Documents

1 file
  • 4
    wk-form4_1781726876.xmlPrimary

    FORM 4